Kamran Alam

Kamran Alam has served as Chief Financial Officer at Taysha Gene Therapies since 2020.

Kamran is a financial executive with over 20 years of experience in finance, operations, and mergers and acquisitions within the biopharmaceutical industry. Throughout his career, Kamran has supported financings that have raised over $1.8 billion across various IPO, follow-on equity and debt financings. Before joining Taysha, Kamran served as Senior Vice President of Finance and Principal Financial Officer at Rocket Pharmaceuticals, where he supported the company through a successful equity financing. Before Rocket Pharmaceuticals, Kamran served as Vice President of Finance at AveXis during the organization’s development and approval of Zolgensma for the treatment of spinal muscular atrophy, the first U.S. FDA approved one-time gene therapy to treat a monogenic CNS disorder. He played a pivotal role in AveXis’ acquisition by Novartis, managing due diligence and post-acquisition integration planning. Prior to AveXis, Kamran served as Senior Director of Finance and Accounting at Aptinyx, and has also held roles in finance and accounting at Naurex, Lundbeck, Ovation Pharmaceuticals and Fresenius Kabi.

A Certified Public Accountant, Kamran earned a B.B.A. from the University of Michigan-Ann Arbor and an M.B.A. in finance from Indiana University-Bloomington.